A resolution expressing support for the designation of June 19, 2026, as "World Sickle Cell Awareness Day" in order to increase public awareness across the United States and global community about sickle cell disease and the continued need for empirical research, early detection screenings, novel effective treatments leading to a cure, and preventative care programs with respect to complications from sickle cell anemia and conditions relating to sickle cell disease.
- Bill Number
- S.Res. 780
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-06-18: Referred to the Committee on Foreign Relations. (text: CR S2939)
- Last Updated
- 2026-07-08T15:17:48Z
AI-Generated Summary
Purpose
This resolution expresses support for designating June 19, 2026, as "World Sickle Cell Awareness Day" to raise public awareness in the United States and worldwide about sickle cell disease (SCD), a group of inherited blood disorders. It highlights the ongoing need for research, early screenings, new treatments toward a cure, and programs to prevent complications.
Key Provisions
- Supports the goals of World Sickle Cell Awareness Day, including the 2026 theme of closing survival gaps and achieving equity in SCD care.
- Commits to ensuring fair access to new SCD treatments across economic, racial, and ethnic groups.
- Calls on the Department of Health and Human Services to develop global policy solutions and partner with local governments for newborn screening, treatments, and support services.
- Supports removing barriers to innovative therapies, such as cell and gene therapies, in Medicare and Medicaid for vulnerable patients.
- Encourages U.S. residents and global communities to hold events and activities on the designated day to promote awareness of SCD traits, prevention, and services.
- Urges the President to create a Sickle Cell Disease Interagency Group involving agencies like the Department of Health and Human Services, Department of Veterans Affairs, National Institutes of Health, Food and Drug Administration, and Centers for Medicare & Medicaid Services.
- Directs the interagency group to address access to future cures while tackling biases faced by affected populations in U.S. and global healthcare systems.
Significant Changes to Existing Law
This is a non-binding Senate resolution and introduces no amendments to current statutes. It references the 1972 National Sickle Cell Anemia Control Act, which first authorized education, screening, and research programs, but does not alter or expand that law.
Potential Impacts
- Government agencies: Encourages the Department of Health and Human Services and related bodies to form new policy groups and expand support for screenings and therapies, potentially requiring coordination across federal departments.
- Citizens: Aims to improve health outcomes for those with SCD through greater awareness, earlier detection, and access to care, especially in communities with higher rates of the condition.
- International relations: Promotes U.S. involvement in global efforts, building on prior World Health Assembly resolutions, to address SCD in regions like sub-Saharan Africa where it affects many children.
Main Stakeholders Affected
- Individuals living with SCD or sickle cell trait, including those in African-American, Hispanic-American, and other affected populations worldwide.
- Federal agencies such as the Department of Health and Human Services, Veterans Affairs, National Institutes of Health, Food and Drug Administration, and Centers for Medicare & Medicaid Services.
- Healthcare providers, researchers, and organizations focused on SCD, including groups like the Sickle Cell Disease Association of America.
- International entities and countries with high SCD prevalence, such as those in Africa, South America, and parts of Asia.
Notable Legal, Constitutional, or Political Implications
As a resolution of support, it carries no legal force but signals congressional priority on health equity and global disease management. It emphasizes addressing biases in healthcare systems without raising constitutional concerns, focusing instead on policy recommendations for fair treatment access.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2026-06-18: Referred to the Committee on Foreign Relations. (text: CR S2939)
- 2026-06-18: Submitted in Senate
Bill Versions
- Expressing support for the designation of June 19, 2026, as "World Sickle Cell Awareness Day" in order to increase public awareness across the United States and global community about sickle cell disease and the continued need for empirical research, early detection screenings, novel effective treatments leading to a cure, and preventative care programs with respect to complications from sickle cell anemia and conditions relating to sickle cell disease. — issued 2026-06-18 — PDF (6 pages)